Engel, Nils W. http://orcid.org/0000-0002-3514-5686
Reinert, Jochim
Borchert, Nora M.
Panagiota, Victoria
Gabdoulline, Razif
Thol, Felicitas
Heuser, Michael
Fiedler, Walter
Funding for this research was provided by:
Deutsche Krebshilfe (70112697)
Deutsche Forschungsgemeinschaft (HE 5240/5-1, HE 5240/5-2, HE5240/6-2)
European Research Council (638035)
Article History
Received: 27 September 2020
Accepted: 15 October 2020
First Online: 27 October 2020
Compliance with ethical standards
:
: F.T. reports advisory role for Abbvie, Astellas, Daiichi Sankyo, Novartis, Celgene, and Pfizer. M.H. reports Honoraria from Novartis, Pfizer and PriME Oncology, Consulting or advisory role for Abbvie, Bayer Pharma AG, Daiichi Sankyo, Novartis and Pfizer, and Research Funding to institution from Astellas, Bayer Pharma AG, BergenBio, Daiichi Sankyo, Karyopharm, Novartis, Pfizer, and Roche. W.F. reports advisory role for Amgen, Pfizer, Novartis, Jazz Pharmaceuticals, Celgene, Morphosys and Ariad/Incyte, Research funding from Amgen, previous support for meeting attendance from Amgen, Jazz Pharmaceuticals, Daiichi Sankyo Oncology and Servier and support in medical writing from Amgen, Pfizer, and AbbVie.
: All procedures in this study involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Written informed consent was waived, given the retrospective nature of this study.
: Not applicable.